M M Gherardi
Overview
Explore the profile of M M Gherardi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rodriguez A, Turk G, Pascutti M, Ferrer F, Najera J, Monaco D, et al.
Virus Res
. 2009 Sep;
146(1-2):1-12.
PMID: 19715734
The HIV epidemic in Argentina is characterized by the high prevalence of infections caused by subtype B and BF variants. In this study, the Nef protein was used as a...
2.
Gherardi M, Ramirez J, Esteban M
Histol Histopathol
. 2001 May;
16(2):655-67.
PMID: 11332721
A main goal of the industrialized world is the development of effective vaccines to control infectious diseases with major health and socio-economic impact. Current understanding of the immune response triggered...
3.
Gherardi M, Gomez M, Garcia V, Sordelli D, Cerquetti M
FEMS Immunol Med Microbiol
. 2000 Oct;
29(2):81-8.
PMID: 11024345
The protection conferred by temperature-sensitive mutants of Salmonella enteritidis against different wild-type Salmonella serotypes was investigated. Oral immunization with the single temperature-sensitive mutant E/1/3 or with a temperature-sensitive thymine-requiring double...
4.
Cerquetti M, Gherardi M
Vet Microbiol
. 2000 Aug;
76(2):185-92.
PMID: 10946148
Chickens were immunized orally with 10(9)cfu of the temperature-sensitive (T(s)) mutant E/1/3 of Salmonella enteritidis at 1, 2, 3 and 7 days of age. The animals were challenged with wild-type...
5.
Ramirez J, Gherardi M, Rodriguez D, Esteban M
J Virol
. 2000 Jul;
74(16):7651-5.
PMID: 10906221
A problem associated with the use of vaccinia virus recombinants as vaccines is the existence of a large human population with preexisting immunity to the vector. Here we showed that...
6.
Gherardi M, Ramirez J, Esteban M
J Virol
. 2000 Jun;
74(14):6278-86.
PMID: 10864637
We previously demonstrated that codelivery of interleukin-12 (IL-12) with the human immunodeficiency virus type 1 (HIV-1) Env antigen from a recombinant vaccinia virus (rVV) can enhance the specific anti-Env cell-mediated...
7.
Ramirez J, Gherardi M, Esteban M
J Virol
. 2000 Jan;
74(2):923-33.
PMID: 10623755
The modified vaccinia virus Ankara (MVA) strain is a candidate vector for vaccination against pathogens and tumors, due to safety concerns and the proven ability of recombinants based on this...
8.
Cerquetti M, Gherardi M
Vaccine
. 1999 Dec;
18(11-12):1140-5.
PMID: 10590336
One-day old chickens were inoculated with temperature-sensitive mutant E/1/3 of S. enteritidis. Two routes of inoculation were used: oral and intraperitoneal (ip). One group of chickens were given two oral...
9.
Gherardi M, Ramirez J, Rodriguez D, Rodriguez J, Sano G, Zavala F, et al.
J Immunol
. 1999 Jun;
162(11):6724-33.
PMID: 10352291
To develop vaccination strategies against HIV-1 infection aimed to specifically enhance the cell-mediated immunity (CMI), we have engineered vaccinia virus (VV) recombinants expressing HIV-1 Env (rVVenv) and murine IL-12 (rVVlucIL-12)...
10.
Gherardi M, Esteban M
Vaccine
. 1999 Apr;
17(9-10):1074-83.
PMID: 10195617
The immune responses elicited after oral delivery of vaccinia virus (VV) recombinants are not well defined. In this study we show with mice, that after oral administration of a VV...